Jacobson Mark L. 4

What Happened
Mark L. Jacobson, Chief Operating Officer of Axsome Therapeutics (AXSM), was granted 19,663 restricted stock units (RSUs) on February 26, 2026. The award was reported as a derivative grant (code A) at $0.00 per share — RSUs represent contingent rights to receive shares in the future rather than an immediate cash purchase or sale.

Key Details

• Transaction date: 2026-02-26 (reported on Form 4 filed 2026-02-27; filing appears timely)
• Grant: 19,663 RSUs; reporting price $0.00 (derivative award, no immediate cash transaction)
• Shares owned after transaction: not specified in the filing
• Footnote summary: (F1) Each RSU equals a contingent right to one share. (F2) Vesting: 25% vests on the one-year anniversary; remaining RSUs vest in three substantially equal annual installments, with full vesting by February 26, 2030. Vested shares will be delivered upon the earlier of a Change in Control, the reporting person’s separation of service (including various termination scenarios), or seven years from the grant date.
• Transaction code: A = Award/Grant (derivative)

Context
RSU grants are a form of compensation and do not indicate an immediate market purchase or sale. Because these units vest over multiple years and are delivered only upon vesting or certain corporate/separation events, they align executive compensation with future performance or retention rather than signaling short-term insider trading activity.